Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

AHA 2026 6 - 9 November 2026

Primary Report of the Ziltivekimab Cardiovascular Outcomes Trial (ZEUS)

Authors :

Paul M Ridker1; A Michael Lincoff2; Nikolaus Marx3; Ann Marie Navar4; Naveed Sattar5; Katherine R Tuttle6; Lance Sloan7; Lale Tokgözoğlu8; Andreas Andersen9; Florian M M Baeres9; Kathrine Ekström9; Mads M D Engelmann9; Sofia Gerward9; G. Kees Hovingh9*; Anders Hvelplund9; and Vlado Perkovic10 on behalf of the ZEUS investigators*Affiliated with Novo Nordisk A/S at the time of the trial conduct

Affiliations
View Details Hide Details
{{ getPageNum(PDFPage) }}
Keywords
Cardiovascular Disease
Congress oral presentation
Anti-IL antibody
Ziltivekimab
PHASE 3 (RCT)